Jump to content



Recommended Posts

FDA has accepted the supplemental Biologics License Application (sBLA) for Tecentriq in combination with chemotherapy for the first-line treatment of people with metastatic non-squamous NSCLC who do not have EGFR or ALK genomic tumor aberrations. https://www.gene.com/media/press-releases/14773/2019-01-16/fda-accepts-genentechs-supplemental-biol 

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.